Ovarian cancer
Ovarian cancer is one of the common tumors of female reproductive organs, and its incidence rate ranks third after cervical cancer and uterine body cancer. However, deaths caused by ovarian cancer account for the first place among all kinds of gynecological tumors, posing a serious threat to women's lives. Due to the complex embryonic development, tissue anatomy and endocrine function of the ovaries, the tumors it suffers from may be benign or malignant. Since ovarian cancer has no symptoms in the early clinical stage, it is quite difficult to distinguish its tissue type and benign or malignant. During laparotomy for ovarian cancer, only 30% of the tumors are found to be confined to the ovaries, and most of them have spread to the uterus, bilateral adnexa, greater omentum and pelvic organs. Therefore, ovarian cancer is indeed a big problem in both diagnosis and treatment. Over the years, experts have conducted many discussions on the pathological morphology, clinical occurrence and development rules and treatment plans of ovarian malignant tumors, and accumulated a lot of experience. So far, according to clinical data statistics at home and abroad, its five-year survival rate is only 25% to 30%.
-
Site of disease:
Ovaries
-
Infectious :
Not contagious
-
Frequent population:
Women aged 30 to 60, mostly occur in perinatal...
-
Related symptoms:
Menstrual disorders
weight loss
lower abdominal pain
lower abdominal mass
postmenopausal bleeding
-
Concurrent disease:
Related Drugs
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Hainan Zhuotai Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Chengdu Beite Denuo Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Shanxi PUDE Pharmaceutical Co., Ltd.
Paclitaxel Injection
Indication: First-line chemotherapy for metastatic ovarian cancer after initial or subsequent chemotherapy failure. Metastatic breast cancer after combined chemotherapy failure or recurrence within 6 months of adjuvant chemotherapy, first-line treatment for advanced non-small cell lung cancer, and adjuvant therapy after surgery for lymph node-positive breast cancer.
Manufacturer:
Shanxi PUDE Pharmaceutical Co., Ltd.
Vinorelbine Tartrate for Injection
Indication: Non-small cell lung cancer, metastatic breast cancer and refractory lymphoma, ovarian cancer, head and neck tumors.
Manufacturer:
Hainan General Alliance Pharmaceutical Co., Ltd.
Cisplatin
Indication: It is the first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is the first-line treatment for SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is the commonly used regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervical, esophageal and urinary system tumors.
Manufacturer:
Qilu Pharmaceutical Co., Ltd.
Megestrol acetate capsules
Indication: It is mainly used to treat advanced breast cancer and advanced endometrial cancer, and also has a certain effect on kidney cancer, prostate cancer and ovarian cancer. It can also improve the appetite and cachexia of patients with advanced tumors.
Manufacturer:
Nanjing Cuccess Pharmaceutical Co., Ltd.
Megestrol acetate capsules
Indication: It is mainly used to treat advanced breast cancer and advanced endometrial cancer, and also has a certain effect on kidney cancer, prostate cancer and ovarian cancer. It can also improve the appetite and cachexia of patients with advanced tumors.
Manufacturer:
Nanjing Cuccess Pharmaceutical Co., Ltd.